Lipigon Pharmaceuticals AB Logo

Lipigon Pharmaceuticals AB

A clinical-stage company developing therapeutics for lipid-related disorders.

LPGO | ST

Overview

Corporate Details

ISIN(s):
SE0015382072
LEI:
549300XPO40YR12SLY87
Country:
Sweden
Address:
Tvistevägen 48 C, 907 36 Umeå

Description

Lipigon Pharmaceuticals is a clinical-stage company specializing in lipid biology, focused on developing novel therapeutics for diseases related to lipid disorders and cardio-metabolic risk factors. The company's lead drug candidate, Lipisense®, is in clinical development for lowering blood triglyceride levels. Lipisense® utilizes a unique mechanism of action to address high blood fats, which are a significant risk factor for cardiovascular disease. The company's pipeline is founded on extensive research in blood lipid regulation, aiming to provide new treatment options for patients with conditions such as severe hypertriglyceridemia and other lipid-related disorders where a significant unmet medical need exists.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lipigon Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lipigon Pharmaceuticals AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lipigon Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-16 Johan Living Other Buy 260,000 51,688.00 SEK

Peer Companies

CAMBRIDGE COGNITION HOLDINGS PLC Logo
Develops digital solutions and a platform for CNS clinical trials to assess brain health.
United Kingdom
COG
A clinical-stage biopharmaceutical company developing novel cancer therapeutics.
Japan
4575
Captor Therapeutics S.A. Logo
Develops Targeted Protein Degradation therapies for cancer and autoimmune diseases.
Poland
CTX
Cardiff Oncology, Inc. Logo
A clinical-stage biotech developing cancer therapies that inhibit Polo-like kinase 1.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
Develops AI-powered epigenetic and genetic tests for early heart disease detection.
United States of America
CDIO
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing treatments for Central Nervous System disorders.
United States of America
SAVA
Celcuity Inc. Logo
Clinical-stage biotech developing targeted therapies for multiple solid tumors.
United States of America
CELC
Develops and manufactures cellulose-based nonwoven fabrics for the cosmetics sector.
South Korea
318160
CEL SCI CORP Logo
Clinical-stage biotech developing immunotherapies for cancer and infectious diseases.
United States of America
CVM
Celyad Oncology SA Logo
Biotechnology company developing innovative CAR-T cell therapies to treat cancer.
Belgium
CYAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.